Ipsen announces it is no longer eligible for the PEA-PME scheme
Ipsen (Euronext: IPN; ADR: IPSEY) announces that the Group is no longer eligible for the PEA-PME scheme (a French equity savings vehicle for small and mid-sized business enterprises) as of January 1st, 2018, in accordance with Articles L221-32-2 and D221-113-5 of the French Monetary and Financial Code.
As of January 1st, 2018, the Group will no longer comply with the thresholds set by the legislator for eligibility to the PEA-PME scheme, determined on the basis of two fiscal years preceding the acquisition date of the securities i.e. the consolidated financial statements for 2016, in accordance with the French regulations.
Consequently, Ipsen Group’s securities can no longer be included in PEA-PME accounts but are still eligible for the traditional PEA scheme.
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
Ipsen announces change in R&D leadership: Howard Mayer to retire, succeeded by Christelle Huguet
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
Ipsen delivers solid H1 2023 results and upgrades its full-year guidance
Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights – effective from...
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
Ipsen announces European Commission decision on palovarotene for the treatment of FOP